Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2010 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Yang T.-S.; CHIUN HSU ; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN ; ZHONG-ZHE LIN ; Chao T.-Y.; ANN-LII CHENG | British Journal of Cancer | 114 | 112 | |
2022 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Zhu A.X.; Abbas A.R.; de Galarreta M.R.; Guan Y.; Lu S.; Koeppen H.; Zhang W.; CHIH-HUNG HSU ; He A.R.; Ryoo B.-Y.; Yau T.; Kaseb A.O.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Wang Y. | Nature Medicine | 108 | 115 | |
2013 | Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma | Toh H.C.; PEI-JER CHEN ; Carr B.I.; Knox J.J.; Gill S.; Ansell P.; McKeegan E.M.; Dowell B.; Pedersen M.; Qin Q.; Qian J.; Scappaticci F.A.; Ricker J.L.; Carlson D.M.; Yong W.P. | Cancer | 102 | 89 |